Sivik Global Healthcare LLC Lowers Position in Humana Inc. (NYSE:HUM)

Sivik Global Healthcare LLC reduced its position in shares of Humana Inc. (NYSE:HUM) by 14.3% in the 4th quarter, HoldingsChannel reports. The firm owned 15,000 shares of the insurance provider’s stock after selling 2,500 shares during the period. Humana comprises approximately 2.9% of Sivik Global Healthcare LLC’s holdings, making the stock its 12th largest position. Sivik Global Healthcare LLC’s holdings in Humana were worth $6,867,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Rakuten Securities Inc. purchased a new stake in Humana during the fourth quarter worth about $25,000. Gradient Investments LLC increased its position in Humana by 200.0% during the fourth quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 40 shares during the last quarter. Cetera Trust Company N.A purchased a new position in shares of Humana in the 4th quarter worth $28,000. Nvwm LLC lifted its stake in shares of Humana by 41.0% in the 3rd quarter. Nvwm LLC now owns 86 shares of the insurance provider’s stock valued at $42,000 after purchasing an additional 25 shares in the last quarter. Finally, Turtle Creek Wealth Advisors LLC acquired a new position in Humana during the fourth quarter valued at approximately $55,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Insiders Place Their Bets

In other Humana news, Director Jorge S. Mesquita purchased 545 shares of the stock in a transaction dated Tuesday, February 20th. The shares were acquired at an average price of $367.09 per share, for a total transaction of $200,064.05. Following the completion of the acquisition, the director now owns 2,578 shares of the company’s stock, valued at approximately $946,358.02. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.29% of the company’s stock.

Humana Price Performance

Shares of NYSE HUM traded down $1.06 during trading on Tuesday, hitting $302.09. The company had a trading volume of 1,565,451 shares, compared to its average volume of 1,990,495. Humana Inc. has a 52 week low of $299.23 and a 52 week high of $541.21. The business’s 50-day moving average is $325.94 and its 200 day moving average is $392.00. The company has a market cap of $36.40 billion, a P/E ratio of 18.81, a PEG ratio of 1.79 and a beta of 0.45. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.67 and a current ratio of 1.67.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.12 by $1.11. Humana had a return on equity of 17.76% and a net margin of 1.82%. The business had revenue of $29.61 billion for the quarter, compared to analysts’ expectations of $28.52 billion. During the same period in the previous year, the firm posted $9.38 EPS. The company’s quarterly revenue was up 10.7% on a year-over-year basis. Equities research analysts predict that Humana Inc. will post 16.08 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date is Friday, June 28th. Humana’s dividend payout ratio is presently 22.04%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on HUM shares. Stephens decreased their target price on Humana from $550.00 to $430.00 and set an “overweight” rating for the company in a research report on Friday, January 26th. The Goldman Sachs Group cut their price objective on Humana from $450.00 to $385.00 and set a “buy” rating on the stock in a research note on Wednesday, April 3rd. Royal Bank of Canada reduced their price target on shares of Humana from $415.00 to $353.00 and set an “outperform” rating on the stock in a research report on Thursday, April 25th. Cantor Fitzgerald lowered their price objective on Humana from $391.00 to $360.00 and set a “neutral” rating for the company in a research note on Thursday, April 25th. Finally, Jefferies Financial Group dropped their price target on shares of Humana from $411.00 to $381.00 and set a “buy” rating on the stock in a research note on Monday, April 22nd. Eleven investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $424.50.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.